Argitalpenak (27) MARÍA NÚÑEZ NÚÑEZ argitalpenak

2024

  1. Post-publication research integrity concerns in randomized clinical trials: A scoping review of the literature

    International Journal of Gynecology and Obstetrics

2023

  1. Assessing the Integrity of Clinical Trials Included in Evidence Syntheses

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 12

  2. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety

    Frontiers in Pharmacology, Vol. 14

  3. International multi-stakeholder consensus statement on clinical trial integrity

    BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 130, Núm. 9, pp. 1096-1111

  4. Research integrity in randomized clinical trials: A scoping umbrella review

    International Journal of Gynecology and Obstetrics, Vol. 162, Núm. 3, pp. 860-876

2022

  1. Compatibility of prolonged infusion antibiotics during Y-site administration

    Nursing in Critical Care, Vol. 27, Núm. 6, pp. 849-858

  2. Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19

    Frontiers in Immunology, Vol. 13

  3. Predictors of inappropriate antimicrobial prescription: Eight-year point prevalence surveys experience in a third level hospital in Spain

    Frontiers in Pharmacology, Vol. 13

  4. Research integrity in clinical trials: innocent errors and spin versus scientific misconduct

    Current Opinion in Obstetrics and Gynecology, Vol. 34, Núm. 5, pp. 332-339

  5. Second Victim Support at the Core of Severe Adverse Event Investigation

    International journal of environmental research and public health, Vol. 19, Núm. 24

2021

  1. Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation

    Medicina Clinica, Vol. 156, Núm. 12, pp. 602-605

2020

  1. Author Correction: A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance (Nature Microbiology, (2019), 4, 7, (1160-1172), 10.1038/s41564-019-0410-0)

    Nature Microbiology

  2. Dalbavancin is a novel antimicrobial against Gram-positive pathogens: Clinical experience beyond labelled indications

    European Journal of Hospital Pharmacy, Vol. 27, Núm. 5, pp. 310-312

  3. Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 2, pp. 429-433

  4. Randomized, double-blind, controlled trial, phase III, to evaluate the use of platelet-rich plasma versus hyaluronic acid in hip coxarthrosis

    Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 64, Núm. 2, pp. 134-142

  5. Uso de dalbavancina en pacientes en hemodiálisis con infecciones protésicas endovasculares por microorganismos multirresistente.

    Diálisis y trasplante: publicación oficial de la Sociedad Española de Diálisis y Trasplante, Vol. 41, Núm. 2, pp. 18-20

2019

  1. A nonlinear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance

    Nature Microbiology, Vol. 4, Núm. 7, pp. 1160-1172

  2. Indicators of the hospital use of antimicrobial agents based on consumption

    Farmacia Hospitalaria, Vol. 43, Núm. 3, pp. 94-100

2018

  1. Analysis of quality antimicrobial agent use in the emergency department of a tertiary care hospital

    Emergencias, Vol. 30, Núm. 5, pp. 297-302

  2. Potential interactions in a cohort of elderly HIV-positive patients

    Farmacia Hospitalaria, Vol. 42, Núm. 4, pp. 163-167